Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Colorectal Neoplasms

Free Subscription Articles published in Eur J Cancer Retrieve available abstracts of 111 articles: HTML format

Single Articles

May 2024
1. MOREAU M, Alouani E, Flecchia C, Falcoz A, et al
   A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability.
   Eur J Cancer. 2024;202:114033.
   PubMed     Abstract available
   
   
   
2. VAN GEFFEN EGM, Langhout JMA, Hazen SJA, Sluckin TC, et al
   Evolution of clinical nature, treatment and survival of locally recurrent rectal cancer: Comparative analysis of two national cross-sectional cohorts.
   Eur J Cancer. 2024;202:114021.
   PubMed     Abstract available
   
   
   March 2024
3. BARBE R, Belkouchi Y, Menu Y, Cohen R, et al
   Imaging-guided prognostic score-based approach to assess the benefits of combotherapy versus monotherapy with immune checkpoint inhibitors in metastatic MSI-H colorectal cancer patients.
   Eur J Cancer. 2024;202:114020.
   PubMed     Abstract available
   
   
   
4. SPIEKMAN IAC, Zeverijn LJ, Geurts BS, Verkerk K, et al
   Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP).
   Eur J Cancer. 2024;202:113988.
   PubMed     Abstract available
   
   
   
5. LI L
   Comment on: Despite multi-disciplinary team discussions the socioeconomic disparities persist in the oncological treatment of non-metastasized colorectal cancer.
   Eur J Cancer. 2024;202:113982.
   PubMed    
   
   
   
6. YOSHINO T, Hooda N, Younan D, Muro K, et al
   A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness.
   Eur J Cancer. 2024;202:113975.
   PubMed     Abstract available
   
   
   February 2024
7. OSTERMAN E, Syriopoulou E, Martling A, Andersson TM, et al
   Corrigendum to "Despite multi-disciplinary team discussions the socioeconomic disparities persist in the oncological treatment of non-metastasized colorectal cancer" [Eur J Cancer 199 (2024) 113572].
   Eur J Cancer. 2024 Feb 20:113940. doi: 10.1016/j.ejca.2024.113940.
   PubMed    
   
   
   
8. ARAI H, Yang Y, Baca Y, Millstein J, et al
   Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer.
   Eur J Cancer. 2024;201:113914.
   PubMed     Abstract available
   
   
   January 2024
9. OSTERMAN E, Syriopoulou E, Martling A, Andersson TM, et al
   Despite multi-disciplinary team discussions the socioeconomic disparities persist in the oncological treatment of non-metastasized colorectal cancer.
   Eur J Cancer. 2024;199:113572.
   PubMed     Abstract available
   
   
   
10. PASTORINO A, Catalano F, Zalcberg JR, Sobrero A, et al
    Cross-trial comparisons for the adjuvant treatment of MSI colorectal cancer: dare to dream the future scenarios.
    Eur J Cancer. 2024;199:113538.
    PubMed     Abstract available
    
    
    
11. COHEN R, Raeisi M, Chibaudel B, Yoshino T, et al
    Efficacy of immune checkpoint inhibitors for metastatic colorectal cancer with microsatellite instability in second or latter line using synthetic control arms: A non-randomised evaluation.
    Eur J Cancer. 2024;199:113537.
    PubMed     Abstract available
    
    
    
12. KWAKMAN JJM, Bond MJG, Demichelis RM, Koopman M, et al
    Adjuvant chemotherapy in patients with clinically node-negative but pathologically node-positive rectal cancer in the Netherlands: A retrospective analysis.
    Eur J Cancer. 2024;197:113466.
    PubMed     Abstract available
    
    
    December 2023
13. STEMMER A, Margalit O, Serpas V, Strauss G, et al
    Immunotherapy in mismatch repair-deficient metastatic colorectal cancer - Outcome and novel predictive markers.
    Eur J Cancer. 2023;198:113495.
    PubMed     Abstract available
    
    
    
14. MALKA D, Verret B, Faron M, Guimbaud R, et al
    Hepatic arterial oxaliplatin plus intravenous 5-fluorouracil and cetuximab for first-line treatment of colorectal liver metastases: A multicenter phase II trial.
    Eur J Cancer. 2023;195:113400.
    PubMed     Abstract available
    
    
    November 2023
15. HAMERS PAH, Vink GR, Elferink MAG, Moons LMG, et al
    Impact of colorectal cancer screening on survival after metachronous metastasis.
    Eur J Cancer. 2023;196:113429.
    PubMed     Abstract available
    
    
    
16. FAKIH M, Wang C, Sandhu J, Ye J, et al
    Immunotherapy response in microsatellite stable metastatic colorectal cancer is influenced by site of metastases.
    Eur J Cancer. 2023;196:113437.
    PubMed     Abstract available
    
    
    
17. SABERZADEH-ARDESTANI B, Jones JC, McWilliams RR, Tougeron D, et al
    Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting.
    Eur J Cancer. 2023;196:113433.
    PubMed     Abstract available
    
    
    October 2023
18. PIETRANTONIO F, Bergamo F, Rossini D, Ghelardi F, et al
    Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV.
    Eur J Cancer. 2023;195:113396.
    PubMed     Abstract available
    
    
    September 2023
19. FOX DA, Bhamidipati D, Konishi T, Kaur H, et al
    Endoscopic and imaging outcomes of PD-1 therapy in localised dMMR colorectal cancer.
    Eur J Cancer. 2023;194:113356.
    PubMed     Abstract available
    
    
    
20. RASOLA C, Laurent-Puig P, Andre T, Falcoz A, et al
    Time to recurrence and its relation to survival after recurrence in patients resected for stage III colon cancer.
    Eur J Cancer. 2023;194:113321.
    PubMed     Abstract available
    
    
    
21. SHA S, Chen LJ, Brenner H, Schottker B, et al
    Associations of 25-hydroxyvitamin D status and vitamin D supplementation use with mortality due to 18 frequent cancer types in the UK Biobank cohort.
    Eur J Cancer. 2023;191:113241.
    PubMed     Abstract available
    
    
    
22. LIN Q, Ding K, Zhao R, Wang H, et al
    Preoperative chemotherapy prior to primary tumour resection for asymptomatic synchronous unresectable colorectal liver-limited metastases: The RECUT multicenter randomised controlled trial.
    Eur J Cancer. 2023;191:112961.
    PubMed     Abstract available
    
    
    August 2023
23. SHKURTI J, van den Berg K, van Erning FN, Lahaye MJ, et al
    Diagnostic accuracy of CT for local staging of colon cancer: A nationwide study in the Netherlands.
    Eur J Cancer. 2023;193:113314.
    PubMed     Abstract available
    
    
    
24. REHMAN OU, Fatima E, Arabpour J
    The association of excessive soft drinks consumption with early-onset colorectal cancer.
    Eur J Cancer. 2023;192:113242.
    PubMed    
    
    
    
25. BOCCACCINO A, Rossini D, Raimondi A, Carullo M, et al
    Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials.
    Eur J Cancer. 2023;189:112910.
    PubMed     Abstract available
    
    
    July 2023
26. YU JH, Xiao BY, Tang JH, Li DD, et al
    Efficacy of PD-1 inhibitors for colorectal cancer and polyps in Lynch syndrome patients.
    Eur J Cancer. 2023;192:113253.
    PubMed     Abstract available
    
    
    
27. TINGUELY P, Ruiter SJS, Engstrand J, de Haas RJ, et al
    A prospective multicentre trial on survival after Microwave Ablation VErsus Resection for Resectable Colorectal liver metastases (MAVERRIC).
    Eur J Cancer. 2023;187:65-76.
    PubMed     Abstract available
    
    
    
28. BUISMAN FE, Grunhagen DJ, Verhoef C, Groot Koerkamp B, et al
    Response to letter entitled: Re: Predicting 10-year survival after resection of colorectal liver metastases; an international study including biomarkers and perioperative treatment.
    Eur J Cancer. 2023;188:80.
    PubMed    
    
    
    June 2023
29. BALLHAUSEN A, Karthaus M, Fruehauf S, Graeven U, et al
    Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) tr
    Eur J Cancer. 2023;190:112955.
    PubMed     Abstract available
    
    
    
30. RAIMONDI A, Nichetti F, Stahler A, Wasan HS, et al
    Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials.
    Eur J Cancer. 2023;190:112945.
    PubMed     Abstract available
    
    
    
31. VAN DE SCHOOTBRUGGE-VANDERMEER, Lansdorp-Vogelaar I, de Jonge L, van Vuuren AJ, et al
    Socio-demographic and cultural factors related to non-participation in the Dutch colorectal cancer screening programme.
    Eur J Cancer. 2023;190:112942.
    PubMed     Abstract available
    
    
    
32. BACHET JB, Laurent-Puig P, Meurisse A, Bouche O, et al
    Circulating tumour DNA at baseline for individualised prognostication in patients with chemotherapy-naive metastatic colorectal cancer. An AGEO prospective study.
    Eur J Cancer. 2023;189:112934.
    PubMed     Abstract available
    
    
    
33. BASCOUL-MOLLEVI C, Gourgou S, Borg C, Etienne PL, et al
    Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER PRODIGE 23): Health-related quality of life longitudinal analysis.
    Eur J Cancer. 2023;186:151-165.
    PubMed     Abstract available
    
    
    May 2023
34. DEDING U, Kaalby L, Steele R, Al-Najami I, et al
    Faecal haemoglobin concentration predicts all-cause mortality.
    Eur J Cancer. 2023;184:21-29.
    PubMed     Abstract available
    
    
    
35. BAHADOER RR, Hospers GAP, Marijnen CAM, Peeters KCMJ, et al
    Risk and location of distant metastases in patients with locally advanced rectal cancer after total neoadjuvant treatment or chemoradiotherapy in the RAPIDO trial.
    Eur J Cancer. 2023;185:139-149.
    PubMed     Abstract available
    
    
    April 2023
36. BOLHUIS K, Bond MJG, Van Amerongen MJ, Komurcu A, et al
    The role of tumour biological factors in technical anatomical resectability assessment of colorectal liver metastases following induction systemic treatment: An analysis of the Dutch CAIRO5 trial.
    Eur J Cancer. 2023;183:49-59.
    PubMed     Abstract available
    
    
    March 2023
37. MANCA P, Corti F, Intini R, Mazzoli G, et al
    Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors.
    Eur J Cancer. 2023;187:15-24.
    PubMed     Abstract available
    
    
    
38. VAN LIERE ELSA, van Dijk LJ, Bosch S, Vermeulen L, et al
    Urinary volatile organic compounds for colorectal cancer screening: A systematic review and meta-analysis.
    Eur J Cancer. 2023;186:69-82.
    PubMed     Abstract available
    
    
    
39. RIJKEN A, van Erning FN, Rovers KP, Lemmens VEPP, et al
    On the origin of peritoneal metastases.
    Eur J Cancer. 2023;181:1-2.
    PubMed    
    
    
    
40. ZHAI LL, Zhu AK, Zhu ZQ, Yin DL, et al
    Letter re: Predicting 10-year survival after resection of colorectal liver metastases: an international study including biomarkers and perioperative treatment: Several additional analysis methods.
    Eur J Cancer. 2023;182:98-99.
    PubMed    
    
    
    February 2023
41. LE DT, Diaz LA Jr, Kim TW, Van Cutsem E, et al
    Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164.
    Eur J Cancer. 2023;186:185-195.
    PubMed     Abstract available
    
    
    
42. ROSSINI D, Boccaccino A, Carullo M, Antoniotti C, et al
    Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials.
    Eur J Cancer. 2023;184:106-116.
    PubMed     Abstract available
    
    
    
43. DUCREUX M, Tabernero J, Grothey A, Arnold D, et al
    Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer.
    Eur J Cancer. 2023;184:137-150.
    PubMed     Abstract available
    
    
    
44. FRANCOIS E, De Bari B, Ronchin P, Nouhaud E, et al
    Comparison of short course radiotherapy with chemoradiotherapy for locally advanced rectal cancers in the elderly: A multicentre, randomised, non-blinded, phase 3 trial.
    Eur J Cancer. 2023;180:62-70.
    PubMed     Abstract available
    
    
    January 2023
45. NEMLANDER E, Ewing M, Abedi E, Hasselstrom J, et al
    A machine learning tool for identifying non-metastatic colorectal cancer in primary care.
    Eur J Cancer. 2023;182:100-106.
    PubMed     Abstract available
    
    
    
46. GERWERT K, Schorner S, Grosserueschkamp F, Kraeft AL, et al
    Fast and label-free automated detection of microsatellite status in early colon cancer using artificial intelligence integrated infrared imaging.
    Eur J Cancer. 2023;182:122-131.
    PubMed     Abstract available
    
    
    
47. MARGALIT O, Harmsen WS, Shacham-Shmueli E, Voss MM, et al
    Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database.
    Eur J Cancer. 2023;178:162-170.
    PubMed     Abstract available
    
    
    
48. BREEKVELDT ECH, Toes-Zoutendijk E, Spaander MCW, van de Schootbrugge-Vandermeer HJ, et al
    Advanced-stage CRC incidence patterns following the phased implementation of the CRC screening programme in the Netherlands.
    Eur J Cancer. 2023;178:60-67.
    PubMed     Abstract available
    
    
    December 2022
49. CHEN PC, Yeh YM, Chu CT, Su PF, et al
    HER2 amplification in colorectal cancer with brain metastasis: A propensity score matching study.
    Eur J Cancer. 2022;181:62-69.
    PubMed     Abstract available
    
    
    
50. GUO Y, Zhang W, Ying J, Zhang Y, et al
    Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases.
    Eur J Cancer. 2022;181:26-37.
    PubMed     Abstract available
    
    
    November 2022
51. KASPER S, Foch C, Esser R, Lamy FX, et al
    Overall survival with cetuximab every-2-weeks versus standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer in patients with left- and right-sided primary tumour location.
    Eur J Cancer. 2022;180:85-88.
    PubMed    
    
    
    October 2022
52. SOMMERHAUSER G, Kurreck A, Beck A, Fehrenbach U, et al
    Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
    Eur J Cancer. 2022;178:37-48.
    PubMed     Abstract available
    
    
    
53. ARGILES G, Mulet N, Valladares-Ayerbes M, Vieitez JM, et al
    A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial).
    Eur J Cancer. 2022;177:154-163.
    PubMed     Abstract available
    
    
    
54. LAKBIR S, Lahoz S, Cuatrecasas M, Camps J, et al
    Tumour break load is a biologically relevant feature of genomic instability with prognostic value in colorectal cancer.
    Eur J Cancer. 2022;177:94-102.
    PubMed     Abstract available
    
    
    
55. PROCACCIO L, Bergamo F, Gatti M, Chiusole B, et al
    The oncological multidimensional prognostic index is a promising decision-making tool: A real-world analysis in older patients with metastatic colorectal cancer.
    Eur J Cancer. 2022;177:112-119.
    PubMed     Abstract available
    
    
    
56. CHANG C, Cai Z, Cao D
    Letter re: "Systematic review and non-inferiority meta-analysis of randomised phase II/III trials on S-1-based therapy versus 5-fluorouracil- or capecitabine-based therapy in the treatment of patients with metastatic colorectal cancer".
    Eur J Cancer. 2022;177:30-32.
    PubMed    
    
    
    
57. GALJART B, Hoppener DJ, Aerts JGJV, Bangma CH, et al
    Follow-up strategy and survival for five common cancers: A meta-analysis.
    Eur J Cancer. 2022;174:185-199.
    PubMed     Abstract available
    
    
    
58. WANG QX, Xiao BY, Cheng Y, Wu AW, et al
    Anti-PD-1-based immunotherapy as curative-intent treatment in dMMR/MSI-H rectal cancer: A multicentre cohort study.
    Eur J Cancer. 2022;174:176-184.
    PubMed     Abstract available
    
    
    
59. FRANKO J, Yin J, Adams RA, Zalcberg J, et al
    Trajectories of body weight change and survival among patients with mCRC treated with systemic therapy: Pooled analysis from the ARCAD database.
    Eur J Cancer. 2022;174:142-152.
    PubMed     Abstract available
    
    
    September 2022
60. UNTERRAINER M, Deroose CM, Herrmann K, Moehler M, et al
    Imaging standardisation in metastatic colorectal cancer: A joint EORTC-ESOI-ESGAR expert consensus recommendation.
    Eur J Cancer. 2022;176:193-206.
    PubMed     Abstract available
    
    
    
61. KREGTING LM, Olthof EMG, Breekveldt ECH, Aitken CA, et al
    Concurrent participation in breast, cervical, and colorectal cancer screening in the Netherlands.
    Eur J Cancer. 2022;175:180-186.
    PubMed     Abstract available
    
    
    
62. TAIEB J, Svrcek M, Cohen R, Basile D, et al
    Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment.
    Eur J Cancer. 2022;175:136-157.
    PubMed     Abstract available
    
    
    
63. WANG M, Li Y
    Re: A transcriptomic signature that predicts cancer recurrence following hepatectomy in patients with colorectal liver metastases.
    Eur J Cancer. 2022;172:405-406.
    PubMed    
    
    
    
64. WADA Y, Goel A
    Response to letter entitled re: A transcriptomic signature that predicts cancer recurrence after hepatectomy in patients with colorectal liver metastases: Add some analytical strategies would be better.
    Eur J Cancer. 2022;172:407-409.
    PubMed    
    
    
    
65. LUNDBERG FE, Birgisson H, Johannesen TB, Engholm G, et al
    Survival trends in patients diagnosed with colon and rectal cancer in the nordic countries 1990-2016: The NORDCAN survival studies.
    Eur J Cancer. 2022;172:76-84.
    PubMed     Abstract available
    
    
    
66. KIM DY, Kwon YJ, Seo WY, Kim UI, et al
    Tankyrase-selective inhibitor STP1002 shows preclinical antitumour efficacy without on-target toxicity in the gastrointestinal tract.
    Eur J Cancer. 2022;173:41-51.
    PubMed     Abstract available
    
    
    August 2022
67. HONG EK, Chalabi M, Landolfi F, Castagnoli F, et al
    Colon cancer CT staging according to mismatch repair status: Comparison and suggestion of imaging features for high-risk colon cancer.
    Eur J Cancer. 2022;174:165-175.
    PubMed     Abstract available
    
    
    
68. MODEST DP, Karthaus M, Kasper S, Moosmann N, et al
    FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases - The PARLIM trial (AIO KRK 0314).
    Eur J Cancer. 2022;173:297-306.
    PubMed     Abstract available
    
    
    
69. RAUSCH C, Schwicht C, Doedens D, Forstpointner R, et al
    Panitumumab can safely and effectively be substituted for cetuximab in the treatment of BRAF V600Emut metastatic colorectal cancer (mCRC) - A case series.
    Eur J Cancer. 2022;174:37-39.
    PubMed    
    
    
    
70. STAHLER A, Modest DP, Fischer von Weikersthal L, Kaiser F, et al
    First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAV
    Eur J Cancer. 2022;173:194-203.
    PubMed     Abstract available
    
    
    
71. OBERMUELLER T, Hautekiet J, Prigge ES, Arbyn M, et al
    Response to the letter entitled: Re: 'Prognostic value of high-risk HPV DNA and p16(INK4a) immunohistochemistry in anal cancer patients: An individual patient data meta-analysis'.
    Eur J Cancer. 2022;171:282-283.
    PubMed    
    
    
    
72. KAWADA T
    Letter re: Prognostic value of high-risk human papillomavirus DNA and p16INK4a immunohistochemistry in patients with anal cancer: An individual patient data meta-analysis.
    Eur J Cancer. 2022;171:280-281.
    PubMed    
    
    
    July 2022
73. ROS J, Elez E
    Overcoming acquired MET amplification after encorafenib-cetuximab in BRAF-V600E mutated colorectal cancer.
    Eur J Cancer. 2022;172:326-328.
    PubMed    
    
    
    
74. SIMILLIS C, Taylor B, Ahmad A, Lal N, et al
    A systematic review and meta-analysis assessing the impact of body mass index on long-term survival outcomes after surgery for colorectal cancer.
    Eur J Cancer. 2022;172:237-251.
    PubMed     Abstract available
    
    
    
75. LI Y, Mo S, Zhang L, Ma X, et al
    Postoperative circulating tumor DNA combined with consensus molecular subtypes can better predict outcomes in stage III colon cancers: A prospective cohort study.
    Eur J Cancer. 2022;169:198-209.
    PubMed     Abstract available
    
    
    
76. DERANGERE V, Lecuelle J, Lepage C, Aoulad-Ben Salem O, et al
    Combination of CDX2 H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer.
    Eur J Cancer. 2022;172:221-230.
    PubMed     Abstract available
    
    
    June 2022
77. MAZZOLI G, Cohen R, Lonardi S, Corti F, et al
    Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer.
    Eur J Cancer. 2022;172:171-181.
    PubMed     Abstract available
    
    
    
78. WANG J, Xiao Y, Loupakis F, Stintzing S, et al
    Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials.
    Eur J Cancer. 2022;172:22-30.
    PubMed     Abstract available
    
    
    
79. BUISMAN FE, Giardiello D, Kemeny NE, Steyerberg EW, et al
    Predicting 10-year survival after resection of colorectal liver metastases; an international study including biomarkers and perioperative treatment.
    Eur J Cancer. 2022;168:25-33.
    PubMed     Abstract available
    
    
    May 2022
80. DELAYE M, Ibadioune S, Julie C, Marin C, et al
    Rational testing for gene fusion in colorectal cancer: MSI and RAS-BRAF wild-type metastatic colorectal cancer as target population for systematic screening.
    Eur J Cancer. 2022;170:85-90.
    PubMed     Abstract available
    
    
    
81. ROSSINI D, Germani MM, Lonardi S, Pietrantonio F, et al
    Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies.
    Eur J Cancer. 2022;170:64-72.
    PubMed     Abstract available
    
    
    
82. STAHLER A, Stintzing S, von Einem JC, Westphalen Benedikt CB, et al
    Corrigendum to 'Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial'. [European Journal of Cancer 137 (2020) 250-259]
    Eur J Cancer. 2022 May 13. pii: S0959-8049(22)00178.
    PubMed    
    
    
    
83. INADA R, Nagasaka T, Shimokawa M, Ojima H, et al
    Phase 3 trial of sequential versus combination treatment in colorectal cancer: The C-cubed study.
    Eur J Cancer. 2022;169:166-178.
    PubMed     Abstract available
    
    
    
84. KIM RD, Kovari BP, Martinez M, Xie H, et al
    A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer.
    Eur J Cancer. 2022;169:93-102.
    PubMed     Abstract available
    
    
    April 2022
85. ROUSSEAU B, Boukerma AK, Henriques J, Cohen R, et al
    Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II study.
    Eur J Cancer. 2022;168:99-107.
    PubMed     Abstract available
    
    
    
86. HAFLIGER E, Boccaccino A, Lapeyre-Prost A, Perret A, et al
    Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series.
    Eur J Cancer. 2022;168:34-40.
    PubMed     Abstract available
    
    
    
87. HAAG GM, Springfeld C, Grun B, Apostolidis L, et al
    Pembrolizumab and maraviroc in refractory mismatch repair proficient/microsatellite-stable metastatic colorectal cancer - The PICCASSO phase I trial.
    Eur J Cancer. 2022;167:112-122.
    PubMed     Abstract available
    
    
    March 2022
88. ANTONIOTTI C, Germani MM, Rossini D, Lonardi S, et al
    FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies.
    Eur J Cancer. 2022;167:23-31.
    PubMed     Abstract available
    
    
    
89. SWARTJES H, Brouwer NPM, de Nes LCF, van Erning FN, et al
    Incidence, treatment and relative survival of early-onset colorectal cancer in the Netherlands since 1989.
    Eur J Cancer. 2022;166:134-144.
    PubMed     Abstract available
    
    
    
90. DERKSEN JWG, Smit KC, May AM, Punt CJA, et al
    Systematic review and non-inferiority meta-analysis of randomised phase II/III trials on S-1-based therapy versus 5-fluorouracil- or capecitabine-based therapy in the treatment of patients with metastatic colorectal cancer.
    Eur J Cancer. 2022;166:73-86.
    PubMed     Abstract available
    
    
    
91. CHRISTOU N, Bergen ES, Canton C, Le Malicot K, et al
    Impact of diabetes and metformin use on recurrence and outcome in stage II-III colon cancer patients-A pooled analysis of three adjuvant trials.
    Eur J Cancer. 2022;166:100-111.
    PubMed     Abstract available
    
    
    
92. OGAARD N, Reinert T, Henriksen TV, Frydendahl A, et al
    Tumour-agnostic circulating tumour DNA analysis for improved recurrence surveillance after resection of colorectal liver metastases: A prospective cohort study.
    Eur J Cancer. 2022;163:163-176.
    PubMed     Abstract available
    
    
    
93. WADA Y, Shimada M, Morine Y, Ikemoto T, et al
    A transcriptomic signature that predicts cancer recurrence after hepatectomy in patients with colorectal liver metastases.
    Eur J Cancer. 2022;163:66-76.
    PubMed     Abstract available
    
    
    February 2022
94. ANTONIOTTI C, Marmorino F, Boccaccino A, Martini S, et al
    Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer.
    Eur J Cancer. 2022;165:116-124.
    PubMed     Abstract available
    
    
    
95. STOUVENOT M, Meurisse A, Saint A, Buecher B, et al
    Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies.
    Eur J Cancer. 2022;162:138-147.
    PubMed     Abstract available
    
    
    January 2022
96. WANG Z, Qin BD, Ye CY, Wang MM, et al
    Cetuximab and vemurafenib plus FOLFIRI (5-fluorouracil/leucovorin/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): An open-label, single-arm, phase II trial.
    Eur J Cancer. 2022;163:152-162.
    PubMed     Abstract available
    
    
    
97. PAPAMICHAEL D, Lopes GS, Olswold CL, Douillard JY, et al
    Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer >/= 70 years.
    Eur J Cancer. 2022;163:1-15.
    PubMed     Abstract available
    
    
    December 2021
98. RANDON G, Intini R, Cremolini C, Elez E, et al
    Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer.
    Eur J Cancer. 2021;161:90-98.
    PubMed     Abstract available
    
    
    
99. DERCLE L, Zhao B, Gonen M, Moskowitz CS, et al
    An imaging signature to predict outcome in metastatic colorectal cancer using routine computed tomography scans.
    Eur J Cancer. 2021 Dec 13. pii: S0959-8049(21)01187.
    PubMed     Abstract available
    
    
    
100. STELZNER S, Puffer E, Zimmer J, Bleyl D, et al
     Significant decrease of the pathological stage I rectal carcinoma in the era of neoadjuvant therapy-A matter of concern.
     Eur J Cancer. 2021;159:275-282.
     PubMed     Abstract available
     
     
     November 2021
101. TOES-ZOUTENDIJK E, Vink G, Nagtegaal ID, Spaander MCW, et al
     Impact of COVID-19 and suspension of colorectal cancer screening on incidence and stage distribution of colorectal cancers in the Netherlands.
     Eur J Cancer. 2021;161:38-43.
     PubMed     Abstract available
     
     
     
102. WILLS C, He Y, Summers MG, Lin Y, et al
     A genome-wide search for determinants of survival in 1926 patients with advanced colorectal cancer with follow-up in over 22,000 patients.
     Eur J Cancer. 2021;159:247-258.
     PubMed     Abstract available
     
     
     
103. OBERMUELLER T, Hautekiet J, Busto MP, Reynders D, et al
     Prognostic value of high-risk human papillomavirus DNA and p16(INK4a) immunohistochemistry in patients with anal cancer: An individual patient data meta-analysis.
     Eur J Cancer. 2021;157:165-178.
     PubMed     Abstract available
     
     
     
104. DUNN C, Gately L, Gibbs P
     Drinking from the firehose - A clinician's perspective on the challenges of delivering biomarker-driven care in routine practice.
     Eur J Cancer. 2021;157:301-305.
     PubMed     Abstract available
     
     
     October 2021
105. BENHAIM L, Bouche O, Normand C, Didelot A, et al
     Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS).
     Eur J Cancer. 2021;159:24-33.
     PubMed     Abstract available
     
     
     
106. QADERI SM, van der Heijden JAG, Verhoeven RHA, de Wilt JHW, et al
     Trajectories of health-related quality of life and psychological distress in patients with colorectal cancer: A population-based study.
     Eur J Cancer. 2021;158:144-155.
     PubMed     Abstract available
     
     
     
107. KIEHL L, Kuntz S, Hohn J, Jutzi T, et al
     Deep learning can predict lymph node status directly from histology in colorectal cancer.
     Eur J Cancer. 2021;157:464-473.
     PubMed     Abstract available
     
     
     August 2021
108. REPETTO M, Conforti F, Pirola S, Calvello M, et al
     Thymic carcinoma with Lynch syndrome or microsatellite instability, a rare entity responsive to immunotherapy.
     Eur J Cancer. 2021;153:162-167.
     PubMed     Abstract available
     
     
     July 2021
109. VAN REES JM, Elferink MAG, Tanis PJ, de Wilt JHW, et al
     The incidence, treatment and survival of patients with rare types of rectal malignancies in the Netherlands: A population-based study between 1989 and 2018.
     Eur J Cancer. 2021;152:183-192.
     PubMed     Abstract available
     
     
     March 2021
110. SEPPALA TT, Dominguez-Valentin M, Crosbie EJ, Engel C, et al
     Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report.
     Eur J Cancer. 2021;148:124-133.
     PubMed     Abstract available
     
     
     
111. FASSAN M, Milione M, Maddalena G, Cremolini C, et al
     Synaptophysin expression in (V600EBRAF-)mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis.
     Eur J Cancer. 2021;146:145-154.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge.